Alnylam Pharmaceuticals vs Zimmer Biomet Holdings
Alnylam Pharmaceuticals (ALNY), health care, and Zimmer Biomet Holdings (ZBH), health care, side by side on market value, valuation, margins, balance sheet and price change. Higher and lower are marked; neither is called better.
Alnylam Pharmaceuticals is worth $21B on the stock market and Zimmer Biomet Holdings $19.3B: Alnylam Pharmaceuticals is valued at 8% more. Alnylam Pharmaceuticals trades at 7.9 times earnings and Zimmer Biomet Holdings at 25.8; operating margins in their latest fiscal years were 13.5% and 13.3%. Over the past year Alnylam Pharmaceuticals's share price has moved -65.4% and Zimmer Biomet Holdings's +13.8%.
Key facts
- Alnylam Pharmaceuticals market value
- $21B
- Zimmer Biomet Holdings market value
- $19.3B
- Alnylam Pharmaceuticals P/E
- 7.9
- Zimmer Biomet Holdings P/E
- 25.8
- Alnylam Pharmaceuticals revenue
- $3.7BFY to 2025-12-31
- Zimmer Biomet Holdings revenue
- $8.2BFY to 2025-12-31
- Superinvestors holding both
- 1
Market values as of .
| Measure | Alnylam Pharmaceuticals | Zimmer Biomet Holdings |
|---|---|---|
| Sector | Health Care | Health Care |
| Country | ||
| Fiscal year ends | 2025-12-31 | 2025-12-31 |
| Size | ||
| Market cap | $21Bhigher | $19.3Blower |
| Revenue | $3.7Blower | $8.2Bhigher |
| Earnings | $313.7Mlower | $705.1Mhigher |
| Employees | 2,500lower | 17,000higher |
| Total assets | $5Blower | $23.1Bhigher |
| Valuation | ||
| P/E | 7.9lower | 25.8higher |
| P/S | 5.6higher | 2.3lower |
| P/B | 5.8higher | 1.5lower |
| Dividend yield | 0.00%lower | 0.95%higher |
| Profitability | ||
| Operating margin | 13.5%higher | 13.3%lower |
| Balance sheet | ||
| Net assets | $789.2Mlower | $12.7Bhigher |
| Total liabilities | $4.2Blower | $10.4Bhigher |
| Total debt | — | $7.5B |
| Cash on hand | $1.7Bhigher | $591.9Mlower |
| Price change | ||
| Today | -2.02%lower | +0.67%higher |
| 1 year | -65.4%lower | +13.8%higher |
Market value, P/E, P/B, dividend yield and price changes are from live quotes (Yahoo Finance; prices may be delayed 15 minutes or more). Revenue, earnings, operating margin and the balance-sheet figures are from each company's latest annual report filed with the SEC (collected 2026-11-12); a company that reports in another currency is converted to US dollars at the exchange rate of that day. P/S sets today's market value against the latest fiscal year's revenue. “Higher” and “lower” compare the two numbers only; a higher P/E or more debt is not better. Dividend yield and P/B are shown only for companies based in the US. A dash means no figure is on file.
Which superinvestors hold them
From each tracked investor's latest 13F filing. A 13F lists long positions in US-listed shares at a quarter end, filed up to 45 days later.
Both (1)
- Dodge & Cox team0.3% / 1.1%
Alnylam Pharmaceuticals only (3)
Zimmer Biomet Holdings only (9)
- Harry Burn2.2%
- Bill Nygren1.5%
- Sarah Ketterer0.4%
- Louis Bacon0.3%
- Brandon Haley0.2%
- Primecap team0.2%
- Mario Gabelli0.2%
- Ken Griffin0.2%
- Charles Brandes (founder)0.1%
Percentages are each holding's share of that investor's reported portfolio (under "Both": Alnylam Pharmaceuticals / Zimmer Biomet Holdings). Who owns ALNY · Who owns ZBH
More on Alnylam Pharmaceuticals
Further comparisons
Alnylam Pharmaceuticals against its closest peers
Zimmer Biomet Holdings against its closest peers
Learn
Questions and answers
Which is bigger, Alnylam Pharmaceuticals or Zimmer Biomet Holdings?
By market value, Alnylam Pharmaceuticals is the larger: $21B against $19.3B for Zimmer Biomet Holdings. By revenue in its latest fiscal year, Zimmer Biomet Holdings is the larger: $8.2B against $3.7B for Alnylam Pharmaceuticals.
Which has the higher P/E ratio?
Zimmer Biomet Holdings: 25.8, against 7.9 for Alnylam Pharmaceuticals. A higher P/E means the market pays more for each dollar of the last twelve months' earnings; on its own it does not say which is the better value.
Which has the higher operating margin?
Alnylam Pharmaceuticals: 13.5%, against 13.3% for Zimmer Biomet Holdings. Operating margin is operating income as a share of revenue in the latest fiscal year.
Which has the higher dividend yield?
Zimmer Biomet Holdings: 0.95%, against 0.00% for Alnylam Pharmaceuticals. Dividend yield is the last twelve months' dividends as a share of today's share price.
Which superinvestors own both Alnylam Pharmaceuticals and Zimmer Biomet Holdings?
In their latest 13F filings, Dodge & Cox team holds both.
Cite this page
Funkfolio, “Alnylam Pharmaceuticals vs Zimmer Biomet Holdings”, data as of 18 November 2026. https://funkfolio.com/compare/alny-vs-zbh
Underlying data: Yahoo Finance quotes; SEC annual reports collected 2026-11-12; 13F filings.